Lisa Maria Mustachio
Papers
1
Total Citations
49
H-Index
1
About
Dr. Lisa Maria Mustachio is a leading cancer biologist whose work centers on the molecular mechanisms of lung cancer and the development of next-generation targeted therapies. Her most impactful contributions focus on the role of cyclin-dependent kinases (CDKs) in driving tumorigenesis and the induction of a unique cell death mechanism known as anaphase catastrophe. In her highly cited 2016 study (49 citations), Dr. Mustachio investigated the novel CDK2/9 inhibitor CCT68127, demonstrating its superior potency over first-generation agents like seliciclib. She showed that this compound effectively triggers multipolar anaphase and subsequent apoptosis in lung cancer cells harboring supernumerary centrosomes, thereby exploiting a critical vulnerability in malignant cells. This work not only advanced the understanding of CDK inhibitor pharmacology but also established anaphase catastrophe as a viable therapeutic strategy. Dr. Mustachio’s research bridges fundamental cell cycle biology with translational drug development, providing a framework for designing more selective and effective treatments for lung cancer patients. Her findings continue to inform the rational design of clinical trials targeting CDK-driven malignancies.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016